Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16462512 | 1.00 | CTSK (0.65) | CTSKATMCTSSCCKBRBACE1 | |
| SCHEMBL5457816 | 0.89 | CTSK (0.55) | CTSKATMCTSSBACE1CTSL | |
| SCHEMBL5457812 | 0.89 | CTSK (0.55) | CTSKATMCTSSBACE1CTSL | |
| SCHEMBL8369521 | 0.88 | CYP3A4 (0.52) | CTSK | |
| SCHEMBL17097354 | 0.86 | ATM (0.58) | CTSKATMCTSSBACE1CTSL | |
| SCHEMBL16482788 | 0.86 | ATM (0.58) | CTSKATMCTSSBACE1CTSL | |
| SCHEMBL16463143 | 0.86 | ATM (0.58) | CTSKATMCTSSBACE1CTSL | |
| SCHEMBL10571494 | 0.84 | BACE1 (0.60) | BACE1 | |
| SCHEMBL7429906 | 0.83 | CTSK (0.49) | CTSKATMCTSSBACE1CTSL | |
| SCHEMBL17106924 | 0.82 | CTSK (0.65) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | HOFFMANN-LA ROCHE INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274777-A1 | KETOAMIDE IMMUNOPROTEASOME INHIBITORS | PSMB7, PSMB5, PSMC2 | CTSK 114/4885ATM 4475/4885CTSS 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.